Soy Linked to Prolonged Survival in Some Breast Cancer Patients

This article originally appeared here.
Share this content:
Soy Linked to Prolonged Survival in Some Breast Cancer Patients
Soy Linked to Prolonged Survival in Some Breast Cancer Patients

WEDNESDAY, March 8, 2017 (HealthDay News) -- Breast cancer survivors who consume more soy may have a lower risk of all-cause mortality over a 10-year period, according to a study published online March 6 in Cancer.

All of the 6,235 participants in the new study were enrolled in the Breast Cancer Family Registry, which began in 1995. At the study's start, the women averaged 52 years of age. During the study, 1,224 of the participants died. The research team tracked data on all the women's diets, some obtained even before they had received their diagnosis of breast cancer.

The researchers found an association between higher soy intake and better survival after breast cancer diagnosis. The benefit was strongest for women who did not have hormone-receptor positive cancers: These women had a 51 percent reduced risk of dying from any cause during the follow-up. Women who had never taken hormone therapy for menopause also appeared to gain a substantial benefit from high soy intake: a 32 percent reduced risk of death during the follow-up period.

"I think now we can say women with breast cancer should not worry about going out to eat edamame, miso soup, tofu, and other soy products, and [to] drink soy milk," Omer Kucuk, M.D., a professor of medical oncology and director of the Integrative Medicine Center at Emory University's Winship Cancer Institute in Atlanta, and author of an editorial accompanying the study, told HealthDay.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »